Wockhardt launches generic midazolam injections in the US
This article was originally published in Scrip
Wockhardt has launched preservative-free midazolam injections 1mg/ml and 5mg/ml in the US. The product is a generic version of Roche's Versed for acute insomnia and anxiety and represents Wockhardt's fourth injection ANDA approval in the past two months and the twelfth sterile product to be approved in the US. Wockhardt now has FDA approval for both preservative-free injections containing midazolam, and midazolam injections containing preservatives. The injections are manufactured at Wockhardt's US FDA-certified formulation plant in Waluj. The US market for midazolam injections is estimated at $56 million.